Bonnar 1996.

Methods	RCT: computer‐generated randomization list to 1 of 3 groups No blinding mentioned
Participants	Country: UK No: 76 Age: 35 to 46 years Inclusion criteria: women reporting HMB confirmed to have > 80 mL per cycle loss, normal cervical smear 3 to 12 months before commencing the study Exclusion criteria: organic causes of menorrhagia found at hysteroscopy or endometrial biopsy, previous renal or hepatic impairment, VTE, inflammatory bowel disease, peptic or intestinal ulceration, coagulation or fibrinolytic disorders
Interventions	Ethamsylate 500 mg 4 times daily for days 1 to 5 of cycle (27 participants) TXA 1 g 4 times daily for days 1 to 5 of cycle (26 participants) MFA 500 mg 3 times daily for days 1 to 5 of cycle (23 participants) Duration: 3 placebo cycles and 3 treatment cycles
Outcomes	MBL: objective measurement (alkaline haematin method), duration of blood loss (days), participant's estimate of blood loss, number of sanitary towels used (end scores and change scores) Dysmenorrhoea Side effects
Notes	Clarification of data sought from authors and reply received Funded by the Health Research Board of Ireland and Pharmacia (a drug company)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomized "by a computer generated randomization list"
Allocation concealment (selection bias)	Unclear risk	Unclear
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details; blinding not mentioned
Incomplete outcome data (attrition bias) All outcomes	Low risk	5 withdrew after randomization (2 in MFA group, 2 in ethamsylate group, 1 in TXA group) and lost to follow‐up
Selective reporting (reporting bias)	Low risk	All pre‐determined outcomes were reported and were relevant
Other bias	Low risk	Groups appeared comparable at baseline